Market Size of Middle East And Africa Human Insulin Industry
| Study Period | 2019- 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.62 Billion |
| Market Size (2029) | USD 1.95 Billion |
| CAGR (2024 - 2029) | 3.78 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Middle East and Africa Diabetes Treatment Market Analysis
The Middle East And Africa Human Insulin Market size is estimated at USD 1.62 billion in 2024, and is expected to reach USD 1.95 billion by 2029, growing at a CAGR of 3.78% during the forecast period (2024-2029).
In the Middle-East and Africa, Type 1 diabetes forms approximately 10% of the diabetes conditions, and Type 2 contributes to 90%. Type 1 patients need to take insulin throughout their lives while maintaining a healthy diet and regular physical exercise.
Type 2 patients need to eat healthily, remain physically active, and perform regular tests to check their blood glucose levels. They may also need to take oral medication and insulin to control the glucose levels in their blood. There are many complications associated with diabetes, like diabetic ketoacidosis and non-ketotic hyperosmolar coma. Serious long-term complications include heart disease, stroke, kidney failure, foot ulcers, and damage to the eyes.
The insulin market is experiencing significant growth due to the rapid increase in the diabetes population in the Middle East and Africa region. Diabetes has become a major health concern in these regions, with a rising number of individuals being diagnosed with the disease.
One of the primary factors driving the growth of the insulin market in the Middle East and Africa is the changing lifestyle and dietary habits of the population. Urbanization, sedentary lifestyles, and the adoption of unhealthy diets high in sugar and processed foods have contributed to the rise in diabetes cases. As a result, there is a growing demand for insulin to manage and control blood sugar levels among diabetic patients.
Additionally, the aging population in the Middle East and Africa is another significant factor contributing to the increased demand for insulin. With advancing age, the risk of developing diabetes increases, leading to a larger diabetic population that requires insulin therapy.
As the production of insulin is very complex, there are very few companies in the market that manufacture insulin. Thus, there is high competition between these manufacturers, and they always strive to meet the patient's needs and supply the best-quality insulin.
